Respiratory Syncytial Virus-related Death in Children with down Syndrome: The RSV GOLD Study
Löwensteyn, Yvette N.; Phijffer, Emily W.E.M.; Simons, Juliette V.L.; Scheltema, Nienke M.; Mazur, Natalie I.; Nair, Harish; Bont, Louis J.
(2020) Pediatric Infectious Disease Journal, volume 39, issue 8, pp. 665 - 670
(Article)
Abstract
Background: Respiratory syncytial virus (RSV) is a major cause of mortality in children younger than 5 years worldwide. Systematic reviews have shown that Down syndrome (DS) is an independent risk factor for severe RSV infection. We aimed to describe demographic and clinical characteristics of children with DS who died with
... read more
RSV infection. Methods: We performed a retrospective case series in which data were shared by individual researchers, research networks and physicians worldwide as part of the RSV Global Online Database study. We included children with DS who died when younger than 5 years of age with laboratory-confirmed RSV infection. Results: We included 53 children with DS and RSV-related mortality from 20 countries in 5 continents. Five (9.4%) children were from low-income or lower-middle-income countries. Median age at time of death was 6.0 months [interquartile range (IQR): 3.00-12.0]. Thirteen (24.5%) children were born term and had no other risk factors for severe RSV disease. In total, 36 (67.9%) children had congenital heart disease, 8 (15.1%) had chronic lung disease and 1 (1.9%) had congenital immunodeficiency. Duration of hospitalization was significantly longer for children with DS compared with children without DS [median length of stay, 13 days (IQR: 6.8-21.0) vs. 8 days (IQR: 3.0-18.5), P=0.005]. Conclusions: One-fourth of children with DS and RSV-confirmed death did not have risk factors for severe RSV disease, indicating that DS is an important risk factor for RSV-related mortality. Age distribution at time of death demonstrates that maternal vaccination would not be sufficient to protect children with DS against RSV-related mortality.
show less
Download/Full Text
Keywords: acute respiratory tract infection, Down syndrome, mortality, respiratory syncytial virus, Microbiology (medical), Infectious Diseases, Pediatrics, Perinatology, and Child Health, Research Support, Non-U.S. Gov't, Journal Article
ISSN: 0891-3668
Publisher: Lippincott Williams and Wilkins
Note: Funding Information: L.J.B. has regular interaction with pharmaceutical and other industrial partners. He has not received personal fees or other personal benefits. University Medical Centre Utrecht (UMCU) has received major funding (>€100,000 per industrial partner) for investigator initiated studies from AbbVie, MedImmune, Janssen, the Bill and Melinda Gates Foundation, Nutricia (Danone) and MeMed Diagnostics. UMCU has received major cash or in kind funding as part of the public private partnership Innovative Medicines Initiative-funded REspiratory Syncytial virus Consortium in EUrope project from GSK, Novavax, Janssen, AstraZeneca, Pfizer and Sanofi. UMCU has received major funding by Julius Clinical for participating in the International Network For Optimal Resistance Monitoring of RSV study sponsored by MedImmune. UMCU has received minor funding for participation in trials by Regeneron and Janssen from 2015 to 2017 (total annual estimate <€20,000). UMCU received minor funding for consultation and invited lectures by AbbVie, MedImmune, Ablynx, Bavaria Nordic, MabXience, Novavax, Pfizer and Janssen (total annual estimate <€20,000). L.J.B. is the founding chairman of the ReSViNET Foundation. D.E.N. has participated as a member of the speakers’ bureau of AbbVie and speakers’ bureau and advisory board for Sanofi Pasteur. This study was supported by the Bill & Melinda Gates Foundation (grant OPP1148988). Data shared by D.J.N. and colleagues have been collected in studies from Kilifi, Kenya, that received Wellcome Trust funding (102975; 203077). The other authors have no conflicts of interest to disclose. Publisher Copyright: © 2020 Wolters Kluwer Health, Inc. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.
(Peer reviewed)